Related Experiment Video
Updated: May 25, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
[Study on effect of berberine on modulating lipid and CPT I A gene expression]
Hong Wang1, Lingyun Shi, Huafeng Yin
1Department of Pharmnacology, Chongqing Medical University, Chongqing 400016, China. wensai@163.com
Objective:
To investigate the modulating effect on lipid and gene expressions of CPT I A caused by berberine (Ber) in experimental hyperlipidemia rats.
Method:
Male SD rats were randomly divided into 5 groups according to the blood lipid values: normal group, hyperlipidemia group, 300 mg x kg(-1) x d(-1) Ber-treated group, 60 mg x kg(-1) x d(-1) Ber-treated group, and 7.2 mg x kg(-1) x d(-1) lovastatin-treated group. Normal group were fed with base diet and other groups were fed with high fat and cholesterol diet. 12 weeks after drugs were given the TC, TG, LDL-C, and HDL-C from rat blood samples were tested by automatic biochemistry analyzer. Gene expressions of CPT I A and PPARalpha were evaluated by RT-PCR and Western blot, respectively.
Result:
It was shown that Ber significantly decreased TC and LDL-C, but increased HDL-C in dose-dependent manner, elevated expressions of CPT I A mRNA and protein without influence on PPARalpha expression. Similar effects from lovastatin on lipidemia were observed except the Ber effect on CPT I A gene expression.
Conclusion:
Ber has modulating effect on the lipid metabolism, the mechanism of which may be by promoting the CPT I A gene expression.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Lipid Catabolism
Pharmacogenetics of Drug Metabolism: Overview